By Fineline Cube CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration (FDA) has granted clearance to initiate a clinical trial of SYH2095, a Category 1 innovative chemical entity and first-in-class lysine acetyltransferase 6 (KAT6) inhibitor, for the treatment of advanced malignancies.
SYH2095 represents a novel epigenetic anticancer therapy that selectively targets chromatin regulation by inhibiting histone lysine acetylation, thereby blocking open chromatin formation and modulating key oncogenic pathways—including cell cycle progression, estrogen receptor expression, and cellular senescence.
Drug Mechanism & Preclinical Profile
| Feature | Detail |
|---|---|
| Target | KAT6 (lysine acetyltransferase 6) – epigenetic regulator overexpressed in multiple cancers |
| Mechanism | Inhibits histone H3 lysine acetylation → suppresses chromatin accessibility → arrests tumor cell proliferation |
| Preclinical Efficacy | Potent and selective KAT6 inhibition; significant tumor growth suppression in xenograft models |
| Pharmacokinetics | Favorable oral bioavailability, half-life, and tissue distribution |
| Safety | Clean off-target profile; no severe toxicity observed in GLP toxicology studies |
| Innovation Status | Category 1 New Drug (China NMPA classification); wholly owned intellectual property |
Strategic Significance for CSPC
- Global Ambition: First CSPC-originated novel chemical entity to enter U.S. clinical development, signaling shift from generics/APIs to global innovation
- Epigenetic Frontier: KAT6 inhibitors remain an emerging class; SYH2095 could pioneer a new therapeutic axis alongside BET and HDAC inhibitors
- Pipeline Diversification: Complements CSPC’s oncology portfolio, which includes biosimilars and targeted kinase inhibitors
- Partnership Potential: Strong preclinical data package positions SYH2095 as an attractive out-licensing candidate for Western pharma seeking differentiated epigenetic assets
Market & Competitive Context
While no KAT6 inhibitors are yet approved globally, academic and industry interest is rising due to KAT6’s role in therapy-resistant cancers, including certain breast, leukemia, and sarcoma subtypes. CSPC’s move places it among a select group of Chinese innovators advancing mechanistically novel oncology agents into international trials.
Forward‑Looking Statements
This brief reflects regulatory clearance to begin clinical investigation. Trial design, patient enrollment, safety, and efficacy outcomes remain subject to ongoing evaluation and regulatory oversight.-Fineline Info & Tech